Aktis Oncology Inc. Common stock (AKTS)
Stock · NASDAQ · Health Care
$15.07as of 10/16/2026
Price chart
Active signals
High Beta100.0%
BOLL Breakdown98.0%Resistance level
$24.2
Industry
Biotechnology: Pharmaceutical Preparations
About AKTS
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 79
- Website
- www.aktisoncology.com/
Fundamentals
- 1-day range
- $14.84$16.37
- Market cap
- $1.30B
- P/E (trailing)
- —
- P/E (forward)
- -7.05
- EPS (trailing)
- $-2.07
- Dividend yield
- —
- Beta
- 158.96
- Avg. volume
- 361.3K
52-week range
$14.72$34.19
Next earnings: November 12, 2026 · EPS estimate $-0.45
How Aktis Oncology Inc. Common stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Oct 8, 2024 · via SEC EDGAR / Finnhub
Gross Profit-$689.0K(-3%)
Operating Income-$109.99M(-402%)
Forecasts
9 analyst ratings
Buy 93%
Hold 7%
Sell 0%
1-year price forecast
High
$40
+165.5%
Median
$35
+132.3%
Low
$31.5
+109.1%
Aktis Oncology Inc. Common stock Competitors
Chosen by industry and closest market cap.
- AKTSAktis Oncology Inc. Common stock$15.06▼ 5.93%Market cap $1.30BP/E —$14.72$34.19
- XERSXeris Biopharma Holdings Inc. Common Stock$10.31▲ 2.38%Market cap $1.27BP/E —$5.25$11.33
- ETONEton Pharmaceuticals Inc. Common Stock$50.31▼ 1.99%Market cap $1.26BP/E 133.39$14.27$66.37
- MLTXMoonLake Immunotherapeutics Class A Ordinary Shares$9.55▼ 6.92%Market cap $1.33BP/E —$8.8$23.29
- SDGRSchrodinger Inc. Common Stock$22.6▼ 11.30%Market cap $1.33BP/E —$10.95$33.78
- ORICOric Pharmaceuticals Inc. Common Stock$12.35▼ 3.29%Market cap $1.34BP/E —$7.23$14.68
- MNKDMannKind Corporation Common Stock$3.04▼ 4.70%Market cap $1.24BP/E —$2.23$6.51
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| AKTS Aktis Oncology Inc. Common stock | $1.30B | — | $15.06 | ▼ 5.93% | $14.72$34.19 |
| XERS Xeris Biopharma Holdings Inc. Common Stock | $1.27B | — | $10.31 | ▲ 2.38% | $5.25$11.33 |
| ETON Eton Pharmaceuticals Inc. Common Stock | $1.26B | 133.39 | $50.31 | ▼ 1.99% | $14.27$66.37 |
| MLTX MoonLake Immunotherapeutics Class A Ordinary Shares | $1.33B | — | $9.55 | ▼ 6.92% | $8.8$23.29 |
| SDGR Schrodinger Inc. Common Stock | $1.33B | — | $22.6 | ▼ 11.30% | $10.95$33.78 |
| ORIC Oric Pharmaceuticals Inc. Common Stock | $1.34B | — | $12.35 | ▼ 3.29% | $7.23$14.68 |
| MNKD MannKind Corporation Common Stock | $1.24B | — | $3.04 | ▼ 4.70% | $2.23$6.51 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Wedbush Reiterates Outperform on Aktis Oncology, Maintains $35 Price Targetbenzinga · 10/2/2026
- Wedbush Reiterates Outperform on Aktis Oncology, Maintains $35 Price TargetBenzinga · 10/2/2026
- Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3Yahoo · 10/1/2026
- Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519Benzinga · 10/1/2026
- Aktis Oncology, Inc. (AKTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/16/2026
Insider Activity
Insider Actions →Acquired
120.4K
Disposed
74.8K
- Czibere Akos · September 23, 2026 · Option Exercise12.5K @ $4.95
- Czibere Akos · September 23, 2026 · Sale7.4K @ $21.03
- Czibere Akos · September 23, 2026 · Sale5.1K @ $20.19
- Herrmann Ken · July 20, 2026 · Option Exercise1.4K @ $1.91
- Herrmann Ken · July 20, 2026 · Option Exercise3.5K @ $0.08
- Herrmann Ken · July 20, 2026 · Sale1.4K @ $24.56
- Herrmann Ken · July 20, 2026 · Sale3.5K @ $24.56
- Herrmann Ken · July 17, 2026 · Option Exercise3.1K @ $0.08
- Herrmann Ken · July 17, 2026 · Sale3.1K @ $25.21
- Ron-Bigger Shulamit · July 8, 2026 · Option Exercise50.0K @ $3.66
- Ron-Bigger Shulamit · July 8, 2026 · Sale4.2K @ $28.75
- Ron-Bigger Shulamit · July 8, 2026 · Sale30.0K @ $27.94
- Ron-Bigger Shulamit · July 8, 2026 · Sale15.8K @ $27.13
- Czibere Akos · July 8, 2026 · Option Exercise50.0K @ $4.95
- Czibere Akos · July 8, 2026 · Sale4.4K @ $28.71
Institutional Ownership
March 31, 2026
- Total shares held
- 34.45M
- Total value held
- $550.33M
- Institutional holders
- 65
Top holders this quarter
- Unknown4.84M
- Unknown4.82M
- Unknown3.16M
- Unknown2.32M
- Unknown2.12M
- Unknown2.11M
- Unknown1.59M
- Unknown1.56M
- Unknown1.50M
- Unknown1.45M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
AKTS launches second Phase 1b trial for AKY-2519
Aktis Oncology announced the start of a second Phase 1b clinical trial for its AKY-2519 candidate. The trial follows earlier testing and moves the drug further along the development pathway. This progress adds to the company's pipeline activity while the stock remains in a low RSI region, indicating recent price weakness.
AKTS launches second Phase 1b trial for AKY-2519. Aktis Oncology announced the start of a second Phase 1b clinical trial for its AKY-2519 candidate. The trial follows earlier testing and moves the drug further along the development pathway. This progress adds to the company's pipeline activity while the stock remains in a low RSI region, indicating recent price weakness.